<i>Background:</i> Counterfeit and substandard medicines represent a severe public health issue, particularly in developing nations where their prevalence exacerbates disease resistance and economic challenges. In addition, many deaths in Côte d'Ivoire could be avoided each year if the drugs prescribed against malaria were compliant with regulations and able to effectively treat the disease. <i>Objective:</i> This study aimed to evaluate the quality of artemether-lumefantrine antimalarial combination on the Ivorian illicit market using the GPHF-Minilab® kit. <i>Methods:</i> A total of 15 samples were analyzed through visual inspection, disintegration testing, and TLC for qualitative and semi-quantitative assessments. <i>Results:</i> The findings reveal significant non-conformities, including 20% of samples lacking manufacturer information, 7% without accompanying instructions, and 20% with physical degradation. 93% of samples disintegrated within 30 minutes, meeting pharmacopoeial standards. One sample exceeded the recommended time, indicating substandard manufacturing. Most samples (67%) met active ingredient quantity requirements, but 26% were underdosed, and 7% were overdosed, highlighting manufacturing and storage deficiencies. In view of these results, it appears that the Artemether-lumefantrine drugs seized on the illegal market in Côte d'Ivoire are not of good quality. <i>Conclusion:</i> The GPHF-Minilab® proves a reliable tool for identifying substandard and counterfeit drugs in resource-limited settings, though further validation is required for broader applications. These results underscore the need for stringent regulatory frameworks, public education, and expanded quality control initiatives.
Read full abstract